NO20081963L - Fremgangsmate for behandling - Google Patents

Fremgangsmate for behandling

Info

Publication number
NO20081963L
NO20081963L NO20081963A NO20081963A NO20081963L NO 20081963 L NO20081963 L NO 20081963L NO 20081963 A NO20081963 A NO 20081963A NO 20081963 A NO20081963 A NO 20081963A NO 20081963 L NO20081963 L NO 20081963L
Authority
NO
Norway
Prior art keywords
ocular neovascular
administration
treating
treatment
methods
Prior art date
Application number
NO20081963A
Other languages
English (en)
Norwegian (no)
Inventor
Richard Anthony Brigandi
Mark Levick
William Henry Miller
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20081963L publication Critical patent/NO20081963L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20081963A 2005-11-29 2008-04-25 Fremgangsmate for behandling NO20081963L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74047805P 2005-11-29 2005-11-29
PCT/US2006/045776 WO2007064752A2 (en) 2005-11-29 2006-11-29 Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema

Publications (1)

Publication Number Publication Date
NO20081963L true NO20081963L (no) 2008-08-26

Family

ID=38037895

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081963A NO20081963L (no) 2005-11-29 2008-04-25 Fremgangsmate for behandling

Country Status (28)

Country Link
US (1) US20080293691A1 (zh)
EP (2) EP1968594B1 (zh)
JP (1) JP5180834B2 (zh)
KR (1) KR20080071188A (zh)
CN (1) CN101370505B (zh)
AT (1) ATE482708T1 (zh)
AU (2) AU2006320535B2 (zh)
BR (1) BRPI0619057A2 (zh)
CA (1) CA2631173A1 (zh)
CR (1) CR10010A (zh)
CY (1) CY1111047T1 (zh)
DE (1) DE602006017261D1 (zh)
DK (1) DK1968594T3 (zh)
EA (1) EA016227B1 (zh)
ES (2) ES2392030T3 (zh)
HK (1) HK1121386A1 (zh)
HR (1) HRP20100559T1 (zh)
IL (1) IL191027A0 (zh)
MA (1) MA30044B1 (zh)
MX (1) MX2008006379A (zh)
MY (1) MY144750A (zh)
NO (1) NO20081963L (zh)
NZ (1) NZ568075A (zh)
PL (1) PL1968594T3 (zh)
PT (1) PT1968594E (zh)
SI (1) SI1968594T1 (zh)
UA (1) UA94427C2 (zh)
WO (1) WO2007064752A2 (zh)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3069576A1 (en) * 2008-01-09 2009-07-16 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of ocular inflammatory disorders
US8076475B2 (en) * 2008-03-06 2011-12-13 Glaxosmithkline Llc Process
SG173167A1 (en) 2009-01-29 2011-08-29 Forsight Labs Llc Posterior segment drug delivery
MX2012000706A (es) * 2009-07-16 2012-06-01 Glaxo Wellcome Mfg Pte Ltd Metodo de tratamiento.
EP2490536A4 (en) * 2009-10-23 2013-04-17 Glaxo Wellcome Mfg Pte Ltd COMPOSITION AND METHOD
WO2011058179A1 (en) 2009-11-16 2011-05-19 Ratiopharm Gmbh 5- (4- (n- (2, 3 -dimethyl- 2h- indazol- 6 -yl) -n-methylamino) pyrimidin- 2 -ylamino) -2 -methylbenzenesulfonamide
WO2011069053A1 (en) 2009-12-04 2011-06-09 Teva Pharmaceutical Industries Ltd. Process for the preparation of pazopanip hcl and crystalline forms of pazopanib hcl
TW201201808A (en) * 2010-01-06 2012-01-16 Glaxo Wellcome Mfg Pte Ltd Treatment method
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
AR081364A1 (es) * 2010-05-05 2012-08-29 Glaxo Wellcome Mfg Pte Ltd Composiciones farmaceuticas de pazopanib y metodos para su elaboracion
EP2600930B1 (en) 2010-08-05 2021-02-17 ForSight Vision4, Inc. Injector apparatus for drug delivery
CA2890554A1 (en) * 2010-10-07 2012-04-12 Aerpio Therapeutics Inc. Compositions and methods for treating ocular edema, neovascularization and related diseases
WO2012068549A2 (en) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US20140018402A1 (en) * 2011-03-30 2014-01-16 Catholic University Industry Academic Cooperation Foundation Pharmaceutical composition for preventing or treating macular degeneration
WO2013000917A1 (en) 2011-06-28 2013-01-03 Bayer Intellectual Property Gmbh Topical ophthalmological pharmaceutical composition containing regorafenib
JP2014518232A (ja) 2011-06-28 2014-07-28 バイエル・ヘルスケア・エルエルシー ソラフェニブを含有する眼科用局所医薬組成物
CA2848385C (en) 2011-09-16 2021-10-26 Forsight Vision4, Inc. Methods and apparatus to exchange a fluid of an implantable device
US9278099B2 (en) * 2011-10-31 2016-03-08 Novartis Ag Pazopanib formulation
RU2014126070A (ru) 2011-12-01 2016-01-27 Глэксо Груп Лимитед Способы лечения и предотвращения глазных заболеваний
CN102657655B (zh) * 2012-05-17 2014-05-21 大连理工大学 嘧啶胺类化合物在制备乙酰胆碱酯酶抑制剂中的应用
WO2013188283A1 (en) 2012-06-12 2013-12-19 Bayer Healthcare Llc Topical ophthalmological pharmaceutical composition containing sunitinib
US9802923B2 (en) 2012-12-17 2017-10-31 Sun Pharmaceutical Industries Limited Process for the preparation of pazopanib or salts thereof
WO2014097152A1 (en) 2012-12-17 2014-06-26 Ranbaxy Laboratories Limited Process for the preparation of pazopanib or salts thereof
UY35183A (es) 2012-12-21 2014-07-31 Bayer Healthcare Llc Composición farmacéutica oftalmológica tópica que contiene regorafenib
US9968603B2 (en) 2013-03-14 2018-05-15 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
WO2015068175A2 (en) 2013-11-05 2015-05-14 Laurus Labs Private Limited An improved process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP2017524034A (ja) 2014-08-08 2017-08-24 フォーサイト・ビジョン フォー・インコーポレーテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ４， Ｉｎｃ． 受容体型チロシンキナーゼ阻害剤の安定で可溶な製剤およびその調製の方法
KR20170043655A (ko) * 2014-09-09 2017-04-21 아르투로 솔리스 헤레라 멜라닌 및 멜라닌 유사체, 전구체, 및 유도체로 안과 질병, 질환, 및 증상의 치료 및 예방을 위한 방법
AU2015346450B2 (en) 2014-11-10 2020-01-30 Forsight Vision4, Inc. Expandable drug delivery devices and method of use
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
US11306140B2 (en) 2016-01-07 2022-04-19 The Schepens Eye Research Institute, Inc. Therapeutics for ocular immunoinflammatory diseases
BR112018070383A2 (pt) 2016-04-05 2019-02-05 Forsight Vision4 Inc dispositivos para aplicação de fármaco oculares implantáveis
CN106565688B (zh) * 2016-11-11 2018-08-31 重庆医科大学 帕唑帕尼二聚体及其制备方法和用途
EP3694890A4 (en) 2017-10-12 2021-11-03 Immunowake Inc. LIGHT CHAIN ANTIBODY FUSION PROTEIN WITH VEGFR
CA3082891A1 (en) 2017-11-21 2019-05-31 Forsight Vision4, Inc. Fluid exchange apparatus for expandable port delivery system and methods of use
CN110878089A (zh) * 2018-09-05 2020-03-13 江苏豪森药业集团有限公司 一种盐酸帕唑帕尼的制备方法
JP2022553640A (ja) 2019-10-10 2022-12-26 コディアック サイエンシーズ インコーポレイテッド 眼障害を処置する方法
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3416530A (en) 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet
US3828777A (en) 1971-11-08 1974-08-13 Alza Corp Microporous ocular device
US4014335A (en) 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US4300557A (en) 1980-01-07 1981-11-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for treating intraocular malignancies
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US5147647A (en) 1986-10-02 1992-09-15 Sohrab Darougar Ocular insert for the fornix
US5322691A (en) 1986-10-02 1994-06-21 Sohrab Darougar Ocular insert with anchoring protrusions
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
DE3905050A1 (de) 1989-02-18 1990-08-30 Lohmann Therapie Syst Lts Therapeutisches system zur verzoegerten und gesteuerten transdermalen oder transmucosalen verabreichung von wirkstoffen (ii)
US4946450A (en) 1989-04-18 1990-08-07 Biosource Genetics Corporation Glucan/collagen therapeutic eye shields
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5290892A (en) 1990-11-07 1994-03-01 Nestle S.A. Flexible intraocular lenses made from high refractive index polymers
US5770592A (en) 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5679666A (en) 1991-11-22 1997-10-21 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids
US5178635A (en) 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
FR2690846B1 (fr) 1992-05-05 1995-07-07 Aiache Jean Marc Forme galenique pour administration oculaire et procede de preparation.
WO1995003009A1 (en) 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5516522A (en) 1994-03-14 1996-05-14 Board Of Supervisors Of Louisiana State University Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
US5710165A (en) 1994-07-06 1998-01-20 Synthelabo Use of polyamine antagonists for the treatment of glaucoma
AUPM897594A0 (en) 1994-10-25 1994-11-17 Daratech Pty Ltd Controlled release container
ES2191719T3 (es) 1994-11-10 2003-09-16 Univ Kentucky Res Found Dispositivo implantable y recargable de descarga controlada para suministrar farmacos directamente a una parte interna del cuerpo.
US5725493A (en) 1994-12-12 1998-03-10 Avery; Robert Logan Intravitreal medicine delivery
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5773019A (en) 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5824073A (en) 1996-03-18 1998-10-20 Peyman; Gholam A. Macular indentor for use in the treatment of subretinal neovascular membranes
US5743274A (en) 1996-03-18 1998-04-28 Peyman; Gholam A. Macular bandage for use in the treatment of subretinal neovascular members
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US5904144A (en) 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція
US20030125317A1 (en) * 1996-10-02 2003-07-03 Smithkline Beecham Corporation Vitronectin receptor antagonists
WO1999007418A2 (en) 1997-08-11 1999-02-18 Allergan Sales, Inc. Sterile bioerodible implant device with improved biocompatability and method
US5902598A (en) 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US6146366A (en) 1998-11-03 2000-11-14 Ras Holding Corp Device for the treatment of macular degeneration and other eye disorders
US6881736B1 (en) 1999-09-07 2005-04-19 Smithkline Beecham Corporation Vitronectin receptor antagonists
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6660960B2 (en) 1999-12-28 2003-12-09 K. K. Endo Seisakusho Method for manufacturing golf club
US6719750B2 (en) 2000-08-30 2004-04-13 The Johns Hopkins University Devices for intraocular drug delivery
NZ526542A (en) * 2000-12-21 2005-01-28 Glaxo Group Ltd Pyrimidineamines as angiogenesis modulators
US7592016B2 (en) 2001-06-28 2009-09-22 Regents Of The University Of California Methods for preparing and using implantable substance delivery devices
US7195774B2 (en) 2001-08-29 2007-03-27 Carvalho Ricardo Azevedo Ponte Implantable and sealable system for unidirectional delivery of therapeutic agents to tissues
US7749528B2 (en) 2001-08-29 2010-07-06 Ricardo Azevedo Pontes De Carvalho Implantable and sealable medical device for unidirectional delivery of therapeutic agents to tissues
AU2003231730A1 (en) * 2002-05-03 2003-11-17 Alcon, Inc. Method of treating vascular endothelial growth factor mediated vascular disorders using amfenac or nepafenac
MXPA04012860A (es) * 2002-06-17 2005-09-20 Smithkline Beecham Corp Proceso quimico.
US20070208023A1 (en) * 2004-04-16 2007-09-06 Smithkline Beecham Corporation Cancer Treatment Method
NZ596663A (en) * 2004-10-21 2013-07-26 Genentech Inc Use of vegf antagonists in intraocular neovascular disease treatment
WO2006117666A2 (en) * 2005-04-29 2006-11-09 Pfizer Inc. Dosage forms, pharmaceutical compositions and methods for sub-tenon delivery

Also Published As

Publication number Publication date
JP2009517396A (ja) 2009-04-30
WO2007064752A2 (en) 2007-06-07
EP1968594A2 (en) 2008-09-17
WO2007064752A3 (en) 2008-08-14
PL1968594T3 (pl) 2011-03-31
CN101370505B (zh) 2012-03-21
PT1968594E (pt) 2010-11-18
JP5180834B2 (ja) 2013-04-10
AU2010249187A1 (en) 2011-01-06
US20080293691A1 (en) 2008-11-27
BRPI0619057A2 (pt) 2011-09-20
ES2350858T3 (es) 2011-01-27
CA2631173A1 (en) 2007-06-07
AU2006320535B2 (en) 2010-09-23
MY144750A (en) 2011-10-31
UA94427C2 (ru) 2011-05-10
HK1121386A1 (en) 2009-04-24
AU2006320535A1 (en) 2007-06-07
MA30044B1 (fr) 2008-12-01
EA200801168A1 (ru) 2008-10-30
DE602006017261D1 (de) 2010-11-11
EP2329821B1 (en) 2012-08-22
EP2329821A1 (en) 2011-06-08
CY1111047T1 (el) 2015-06-11
IL191027A0 (en) 2009-08-03
ATE482708T1 (de) 2010-10-15
CN101370505A (zh) 2009-02-18
HRP20100559T1 (hr) 2010-11-30
DK1968594T3 (da) 2010-12-13
EP1968594B1 (en) 2010-09-29
ES2392030T3 (es) 2012-12-04
NZ568075A (en) 2010-12-24
SI1968594T1 (sl) 2011-01-31
CR10010A (es) 2008-11-03
EA016227B1 (ru) 2012-03-30
KR20080071188A (ko) 2008-08-01
MX2008006379A (es) 2009-03-03

Similar Documents

Publication Publication Date Title
NO20081963L (no) Fremgangsmate for behandling
ATE500831T1 (de) Krebsbehandlungsverfahren
LTC2201840I2 (lt) Brutono tirozinkinazės inhibitoriai
TW200716139A (en) Methods and compositions for managing psychotic disorders
BRPI0507657A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
EA200400476A1 (ru) Производные аминоиндазола, активные в качестве ингибиторов киназ, способ их получения и содержащая их фармацевтическая композиция
BRPI0414435A (pt) métodos e reagentes para o tratamento de distúrbios imunoinflamatórios
IL186566A0 (en) Substituted 2-amin0alkylth10-benzimidaz0les and use thereof for reducing blood sugar levels
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
NO20060020L (no) 3-fluorpiperidiner som NMDA/NR2B-antagonister
NO20055531L (no) Preparat for forbedret kognisjon og hukommelse
DE602005027677D1 (de) 1,3,4-oxadiazol-2-one als ppar-delta-modulatoren und deren verwendung
NO20064951L (no) 1,3,4-oksadiazol-2-oner som PPAR delta-modulatorer og deres anvendelse
WO2007143483A3 (en) Combination of pazopanib and lapatinib for treating cancer
BR0015416A (pt) Composições contendo derivados do ácido hidroxieicosa tetraenóico e métodos de uso no tratamento de distúrbios de olhos secos
NO20052059D0 (no) Terapier for kronisk inflammatorisk demyeliniserende polynevropati ved anvendelse av interferon-beta.
CY1109666T1 (el) Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας
NO20071704L (no) Prostaglandinderivater for behandling av gastrointestinal forstyrrelse
TW200616625A (en) Agent for prophylaxis or treatment of metabolic syndrome
ATE431147T1 (de) Mittel zur behandlung des integrationsdysfunktionssyndroms
MY134059A (en) Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
EA200500242A1 (ru) Пиперидин-2,5-дионовые памоатные соли и их использование для лечения связанных со стрессом аффективных расстройств
MY128882A (en) Novel use of substituted aminomethyl chromans

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application